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Introduction
Thyroid dysfunction is often invoked as a cause for 
numerous non-specific and nebulous symptoms in the 
absence of supporting clinical findings. In other instances, 
thyroid function tests may be performed as a routine in an 
asymptomatic patient. Abnormal results may be obtained, 
resulting in an erroneous diagnosis. The presence of 
euthyroid hyperthyroxinaemia in these circumstances 
may result in an erroneous diagnosis of hyperthyroidism. 
An unusual cause of euthyroid hyperthyroxinaemia is 
described. 
Case report
A 47-year-old female patient presented to her gynaecologist 
in December 2008 for a routine check-up. She had no 
symptoms relating to her thyroid and reported no loss of 
weight, no nervousness, no palpitations, and no ocular 
symptoms. In fact, she generally felt very well. She had a 
family history of thyroid dysfunction in that her mother had 
hypothyroidism and was taking L-thyroxine. This prompted 
a routine thyroid function test to be performed by the 
gynaecologist. Her thyroid function test was reported to 
indicate hyperthyroidism, but with unsuppressed thyroid-
stimulating hormone (TSH) despite elevated thyroxine 
(T4; Table I). The patient elected to commence with no 
treatment, as she was going on holiday. The patient 
was seen by her gynaecologist again in January 2009, 
during which time her thyroid function test again showed 
elevated T4 with unsuppressed TSH. The patient was again 
completely asymptomatic. Based on the isolated elevated 
T4 result, she was commenced on carbimazole 10 mg daily, 
but discontinued her therapy shortly thereafter as she felt 
very unwell on treatment. She revisited the doctor again in 
June 2009 and, following repeat thyroid function testing that 
yet again indicated the elevated T4 and unsuppressed TSH, 
the patient was referred to our centre.
Clinically, the patient was euthyroid and normal in all 
respects. In view of the clinical findings, a possibility of 
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Abstract
Background: The authors report a case of euthyroid hyperthyroxinaemia and the systematic approach that led to the 
diagnosis. The related literature is also reviewed in an attempt to increase awareness of this condition.
Case report: A 47-year-old female patient was referred for further investigation and management of “hyperthyroidism.” 
The patient was clinically euthyroid and had previously been treated with carbimazole, but self-discontinued therapy as she 
felt unwell on treatment. A careful review of this patient’s blood results revealed elevated free thyroxine and unsuppressed 
thyroid-stimulating hormone (TSH). This is atypical of primary hyperthyroidism, in which case suppressed TSH would have 
been expected. In view of the clinical euthyroidism, euthyroid hyperthyroxinaemia was considered the most likely diagnosis 
and an appropriate work-up was initiated. Following on the consultation with the Chemical Pathology Unit, assay interference 
was established as the likely cause and the patient was reassured. She remains well, with no treatment.
Conclusion: Thyroid function tests should not be interpreted in isolation and, if the clinical picture and biochemistry are 
discordant, it is imperative to consider assay interference. It is also important to apply basic physiological principles in 
interpreting endocrine blood results. In this patient, both the clinical euthyroidism and the unsuppressed TSH, which are 
atypical of primary hyperthyroidism, prompted further work-up.
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assay interference was considered to be the most likely 
explanation for the lack of clinical correlation with the blood 
results. Thyroid hormone resistance and TSH-producing 
tumour was also considered, although deemed less likely.
Blood samples were submitted to the Chemical Pathology 
Unit at Lancet Laboratories in Johannesburg, South Africa 
and analysed in three separate assays. Two showed a 
completely normal result, in keeping with euthyroidism, and 
one showed an elevated T4 and triiodothyronine (T3) in the 
face of unsuppressed TSH (Table I). The Roche Elecsys® 
assay that was showing the abnormal result was analysed 
in more detail, and an interfering factor to the ruthenium 
label was identified in the sample. More detailed analysis 
revealed that all of the previous blood tests that were shown 
to be abnormal had been performed with the Roche assay. 
The patient was reassured and it was recommended to her 
that in the future she should have her blood tests done on 
the assays that showed no interference to avoid confusion 
and unnecessary investigations, treatment and anxiety.
Discussion
The term “euthyroid hyperthyroxinaemia” may be used 
to describe any condition in which serum T4 is increased 
in the absence of thyrotoxicosis.1 Despite a number of 
publications on the subject, conditions causing euthyroid 
hyperthyroxinaemia are frequently unrecognised, and the 
discrepancy between a patient’s clinical state and test 
results is overlooked.2 Much of the literature on euthyroid 
hyperthyroxinaemia is from the 1980s and there have been 
few publications on the topic since then.
Familial dysalbuminaemic hyperthyroxinaemia (FDH) is due 
to albumin with an abnormal binding site that shows much 
greater affinity for thyroxine than the hormone-binding site 
on thyroxine-binding globulin (TBG).3 FDH is an autosomal 
dominant disorder that results in increased total T4, but 
free T4 and total and free T3 remain normal in the otherwise 
euthyroid patient.4 This patient had increased free T4 and 
elevated free T3, and no family history of a similar problem, 
making the diagnosis unlikely.
Causes such as psychiatric illness and drugs could be 
largely excluded by taking the clinical context into account.5 
It is important to interpret thyroid function tests with care 
in acute psychiatric admissions.6 Resistance to thyroid 
hormone (RTH) is uncommon and is characterised by 
reduced responsiveness of the target tissues to circulating 
thyroid hormones. The biochemical hallmark is elevated free 
T4 and non-suppressed pituitary TSH, reflecting resistance 
to thyroid hormone action in the hypothalamic-pituitary-
thyroid axis.5 This patient had no goitre (present in up to 
65% of individuals with RTH) and no symptoms relating 
to her cardiovascular, musculoskeletal or central nervous 
systems, and also no hearing loss or abnormal colour 
vision. Serum immunoglobulins, which may be reduced in 
individuals with RTH, were normal.5 The patient also had 
documented antibody interference and normal free T4 and 
TSH on a two-step assay, thus making the diagnosis of RTH 
unlikely. Factitious hyperthyroxinaemia has been described 
due to immunoglobulin (Ig) A-secreting multiple myeloma.7 
This patient’s serum protein electrophoresis was entirely 
normal.
TSH-secreting pituitary adenoma was excluded by 
normal sex hormone-binding globulin, a normal magnetic 
resonance imaging scan (done for other indications) of the 
pituitary and with normal thyroid function tests on two-step 
assay, and thus other investigations (thyrotropin-releasing 
hormone response, T3 suppression, α-subunit:TSH ratio) 
were not considered necessary.
This patient had euthyroid hyperthyroxinaemia on the basis 
of antibody interference and we will discuss this in more 
detail.
An evaluation of the patient’s laboratory records showed that 
two methods from different manufacturers using different 
principles were used at different times to determine her 
thyroid hormone levels. The ARCHITECT® method (Abbott 
Laboratories) consistently produced results concordant with 
the clinical picture, whereas Elecsys® (Roche Diagnostics) 
appeared to produce results that were discordant with the 
clinical picture in this patient. The ARCHITECT® method for 
free T4 (FT4) and free T3 (FT3) is a two-step assay in which 
Table I: Results of serial thyroid function tests
Elecsys® 2010 (Roche) ARCHITECT® i8200 (Abbott)
Date December 2008 January 2009 June 2009 Normal range July 2009 Normal range
TSH (μIU/ml) 0.39 0.52 0.48 0.27–4.20 0.68 0.35–4.94
Free T3 (pmol/l) - - 12.4 2.8–7.1
Free T4 (pmol/l) 44.4 33.7 32.5 12.0–22.0 13.1 9.0–19.0
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patient serum and labelled FT4/FT3 are separated by a wash 
step. This reduces the sequestration of labelled FT4/FT3 
through nonspecific binding. 
Principle of the FT4/FT3 Roche assay
The FT4/FT3 assay uses an electrochemiluminiscent 
competitive binding immunoassay. This allows results 
to be available in a very short time to allow better patient 
management. The assay is known as a one-step, two 
incubations method. 
First incubation: The patient sample is mixed with specific 
sheep-derived polyclonal antibodies for FT4, or, in the case 
of FT3, with sheep-derived monoclonal antibodies. These 
antibodies are labelled with ruthenium complex [ruthenium 
(II) tris (bipyridyl) complex].
Second incubation: There is no wash step. The reagent 
mixture containing biotinylated T4 (or T3) and streptavidin-
coated paramagnetic microparticles is added. Biotinylated 
T4/T3 binds to any free binding sites of the specific polyclonal 
T4 or monoclonal T3 antibodies. Streptavidin and biotin react 
to form an antibody-hapten complex. The more free binding 
sites are available, the more labelled hormone will bind 
to these sites. The reaction mixture is aspirated into the 
measuring cell, where the microparticles are magnetically 
captured onto the electrode. All unbound substances, 
including serum FT4-ruthenium-labelled specific antibody 
complex, are washed out with Procell®.
The application of a voltage to the electrode induces 
chemiluminiscent emission, which is measured. The 
emission of a chemiluminiscent signal is inversely 
proportional to the hormone present in the patient serum.8
When clinically discrepant results were observed in 
this patient, further investigations that were conducted 
included re-analysis of the same sample by two different 
manufacturers’ methods, rheumatoid factor (RF), thyroid 
autoantibodies, as well as the shipping of sample aliquots 
to Roche for further investigations. 
The two manufacturers’ products yielded discrepant results 
(Table II). The patient was negative for RF and thyroid 
autoantibodies. According to the manufacturer, heterophile 
antibodies (IgG and IgM type) were identified as interfering 
proteins. These antibodies most likely block the ruthenium-
labelled specific T4 and T3 antibodies from binding to 
biotinylated T4/T3, thus causing a signal quench that, in turn, 
results in high FT4/FT3 results.
Polyethylene glycol (PEG) precipitation or dilution studies 
were not carried out on these samples.
Antibody interference in thyroid assays may result in 
apparent abnormal concentrations of thyroid hormones 
inconsistent with the patient’s thyroid state.8 Thyroid 
hormone can be measured with single- or double-antibody 
immunoassays.9 When interpreting thyroid function tests 
it is important to take into account basic physiology, 
as this will allow for internally inconsistent results to be 
appreciated. In primary hyperthyroidism, TSH becomes 
suppressed prior to FT4 and FT3 elevation, in an attempt to 
maintain euthyroidism. The presence of elevated FT4 in the 
presence of TSH that is inappropriately non-suppressed, as 
was the case with this patient, would not be in keeping with 
primary hyperthyroidism.
The presence of circulating, endogenous antibodies 
directed against a number of antigens may cause both 
falsely depressed and falsely increased values in thyroid 
hormones. The outcome largely depends on the nature 
of the interfering antibody or the assay design. The major 
importance of appreciating antibody interference as a 
confounding factor in the interpretation of thyroid function 
tests is that it often leads to inappropriate investigations 
and treatment, as was the case in this patient.
In thyroid hormone immunoassays, the major sources 
of antibody interference are autoantibodies, heterophile 
antibodies and RF. Autoantibodies as interfering factors 
include antibodies to thyroglobulin, microsomal thyroid 
peroxidase and TSH receptor, and antibodies reacting 
with T4 and T3. Many different approaches may be utilised 
to overcome the interference, e.g. PEG precipitation. 
Heterophile antibodies are known to interfere with many 
immunoassays, and are antibodies against specific 
animal immunoglobulins or against immunoglobulins 
of various animal species. The best-known heterophile 
antibodies are human anti-mouse antibodies. RF may also 
exhibit non-specific binding to the analytical antibodies 
and cause interference. The non-specific binding by RF 
may be overcome, as for heterophile antibodies, with 
blocking reagents such as non-immune homologous 
immunoglobulin.10
When interpreting a thyroid function test, it is important to 
consider antibody interference in a patient with discrepant 
Table II: Same sample tested by two methods
Date Method/platform TSH (μIU/mL) FT4 (pmol/L)
21 August 2009 ARCHITECT® 
i8200
0.85 15.3
21 August 2009 Elecsys® 2010 0.35 30.7
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results. Routine communication between the chemical 
pathologist and the clinician is imperative to delineate 
further the nature of the problem. This will allow for a 
discrepancy between the clinical findings and the laboratory 
findings to be followed up, as was the case with this patient. 
The laboratory should then repeat the suspect sample to 
confirm if the interfering antibodies could account for the 
spurious result. Samples are typically re-evaluated using 
an alternative method and the removal of the interfering 
antibody (e.g. by PEG), or by using antibody-blocking 
reagents. Results on reanalysis that are different after the 
removal of interfering antibodies are indicative of antibody 
interference. These results are not reportable, as they may 
not reflect realistic concentrations.
Conclusion
Both chemical pathologists and clinicians must be vigilant 
to the possibility of antibody interference when interpreting 
thyroid function tests, particularly with the finding of 
euthyroid hyperthyroxinaemia. This will prevent unnecessary 
investigations and treatment. This case represents an 
unusual but important problem in clinical endocrinology.
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